Skip to main content
. 2016 Dec 29;107(12):1830–1836. doi: 10.1111/cas.13087

Table 3.

Multivariate logistic regression analysis for prevalence of DILD

Characteristics Category N Multivariate
Odds ratio 95% CI lower 95% CI upper P‐value
Age <65 6299 1 NA NA NA
≥65 2607 0.822 0.483 1.399 0.4709
Sex Male 4990 1 NA NA NA
Female 3916 0.608 0.347 1.064 0.0813
Race White 7692 1 NA NA NA
Black 743 0.897 0.382 2.103 0.8017
Others 471 0.706 0.217 2.293 0.5619
Body surface area 0.1 m2 decrease 8906 1.096 0.990 1.213 0.0784
Treatment M 1609 1 NA NA NA
C 2364 1.035 0.449 2.384 0.9359
M + C 1385 2.553 1.188 5.486 0.0164
M + M 766 2.175 0.873 5.420 0.0952
C + C 783 1.173 0.397 3.466 0.7728
Others 1999 0.646 0.217 1.929 0.4342
Concurrence of radiation therapy No 8705 1 NA NA NA
Yes 201 11.392 3.408 38.076 <0.0001
Previous history of thoracic radiation therapy No 8830 1 NA NA NA
Yes 76 3.166 0.734 13.662 0.1223
Coexistence of pulmonary disease No 8651 1 NA NA NA
Yes 255 1.527 0.513 4.544 0.4468
Smoking history No 8794 1 NA NA NA
Ex‐smoker or current smoker 112 1.605 0.349 7.393 0.5434
Coexistence of lung lesion No 6163 1 NA NA NA
Yes 2743 1.342 0.749 2.406 0.3233
PS 0 2973 1 NA NA NA
≥2 5933 1.872 1.044 3.356 0.0353
Solid or hematological malignancy Solid tumor 7540 1 NA NA NA
Hematology 1366 2.894 1.593 5.258 0.0005
LDH Normal 4403 1 NA NA NA
Elevated 4503 1.146 0.704 1.864 0.5837

†Coexistence of pulmonary disease was defined as patient with lung complication or past‐history such as chronic pulmonary lung disease, bronchial asthma, pulmonary embolism, sarcoidosis, pneumothorax, asbestosis and infection. ‡Coexistence of lung lesion was defined as patient with primary lung tumor and/or lung metastases. C, cytotoxic agent; CI, confidence interval; DILS, drug‐induced interstitial lung disease; LDH, lactate dehydrogenase; M, molecular targeted drug; PS, performance status; NA, not applicable.